Neoplasms

Digestive System Diseases

All Conditions

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Cetuximab

Immunoglobulins

Mitogens

Antineoplastic Agents, Immunological

Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;

Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;

Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.

CPGJ602

Quanrui Wu, Master

Hongming Pan, Doctor

Jianming Xu, Doctor

This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The immunogenicity and preliminary efficacy of CPGJ602 will also be assessed. The study includes 3 parts: part 1: after a single dose of CPGJ602 or cetuximab (the active comparator), the patients will be observed for 4 weeks; part 2: CPGJ602 or cetuximab will be administered to the patients once a week for 5 weeks; part 3: CPGJ602 will be administered to the patients once a week until the patient's death or the withdrawal decision of the patient and/or investigator.

OBJECTIVES:

Primary:

To assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of CPGJ602 administered by intravenous infusion.

Secondary:

To assess the immunogenicity and anti-tumor activity of CPGJ602, compare the pharmacokinetics and immunogenicity between CPGJ602 and the active comparator, cetuximab, and to provide scientific basis for the subsequent phase 2/3 clinical trials.

OUTLINE:

This is an open-label, parallel designed study in patients with at least one prior chemical regimen failed metastatic colorectal cancer. The study can be divided into 3 parts:

Part 1: Single-dose Part

* Arm A: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
* Arm B: CPGJ602, IV over 2 hours, 400 mg/m2 X 1;
* Arm C: Cetuximab, IV over 2 hours, 400 mg/m2 X 1.

Part 2: Multi-dose Part

The subjects from arm A in Part 1 will be randomized into arm B or C.

* Arm B: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
* Arm C: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time. The completion of Day 63 Visit (the visit on the 7th day after the 5th dose in Part 2) can be considered as the completion of the study.

Part 3 (Follow-up Part)

CPGJ602, IV over 1 hour, QW, 250mg/m2, until the patient's death or the withdrawal decision of the patient and/or investigator.

A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

A Phase 1 Study of Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Human-mouse Chimeric Monoclonal Antibody Injection in Patients With Metastatic Colorectal Cancer

part 1 for single dose and part 2 for multiple doses

to evaluate the Immunogenicity; if the result is positive, Neutralizing Antibody \[NAB\] will also be assessed.

the rate of completely response \[CR\] and partial response \[PR\] patients

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer	NCT03356158	Metastatic Colo...	CPGJ602 Cetuximab	18 Years - 70 Years	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer	NCT03356158	Metastatic Colo...	CPGJ602 Cetuximab	18 Years - 70 Years	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Spots Global Cancer Trial Database for metastatic colorectal cancer,